Literature DB >> 30265593

Identification of loci affecting sexually dimorphic patterns for height and recurrent laryngeal neuropathy risk in American Belgian Draft Horses.

Samantha A Brooks1, John Stick2, Ashley Braman2, Katelyn Palermo1, N Edward Robinson2, Dorothy M Ainsworth3.   

Abstract

Equine recurrent laryngeal neuropathy (RLN) is a bilateral mononeuropathy with an unknown etiology. In Thoroughbreds (TB), we previously demonstrated that the haplotype association for height (LCORL/NCAPG locus on ECA3, which affects body size) and RLN was coincident. In the present study, we performed a genome-wide association scan (GWAS) for RLN in 458 American Belgian Draft Horses, a breed fixed for the LCORL/NCAPG risk alelle. In this breed, RLN risk is associated with sexually dimorphic differences in height, and we identified a novel locus contributing to height in a sex-specific manner: MYPN (ECA1). Yet this specific locus contributes little to RLN risk, suggesting that other growth traits correlated to height may underlie the correlation to this disease. Controlling for height, we identified a locus on ECA15 contributing to RLN risk specifically in males. These results suggest that loci with sex-specific gene expression play an important role in altering growth traits impacting RLN etiology, but not necessarily adult height. These newly identified genes are promising targets for novel preventative and treatment strategies.

Entities:  

Keywords:  American Belgian Draft Horse; Myopalladin (); body size; recurrent laryngeal neuropathy (RLN)

Mesh:

Year:  2018        PMID: 30265593     DOI: 10.1152/physiolgenomics.00068.2018

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  1 in total

1.  Genetic mapping of distal femoral, stifle, and tibial radiographic morphology in dogs with cranial cruciate ligament disease.

Authors:  Eleni Healey; Rachel J Murphy; Jessica J Hayward; Marta Castelhano; Adam R Boyko; Kei Hayashi; Ursula Krotscheck; Rory J Todhunter
Journal:  PLoS One       Date:  2019-10-17       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.